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Effect of a heptapeptide angiotensin analog on aldosterone secre-
tion in the rabbit. We examined the effects of an angiotensin Ill
(Aill) analog, isoleucine-7 Aill (11e7-AllI), on the steroidogenic
and pressor responses to angiotensin II (All) and AIlI. All or
AIll (25 ng/kg/min) were infused alone or superimposed on an
infusion of lleT-AlIl (100 ng/kg/min) in conscious male New Zea-
land rabbits. All and All! induced comparable increases in
plasma aldosterone concentration, but All exhibited significant-
ly greater pressor effect. lleT-AIll infusion resulted in significant
inhibition of All- but not Aill-induced steroidogenesis. Despite
inhibition of aldosterone production, lle7-Alll failed to block the
pressor or renin-suppressing effect of Al!. Inhibition of the ste-
roidogenic effect of All, but not of AllI. by lle7-AIil may be
taken as evidence that adrenal stimulation by All is direct and is
not mediated by in vivo conversion to the heptapeptide. The abil-
ity of the heptapeptide analog to block aldosterone stimulation
by the octapeptide All suggests that adrenal receptors may,
however, have a greater affinity for the heptapeptide.
Effet d'un heptapeptide analogue a l'angiotensine sur Ia sécré.
tion d'aldostérone ehez le lapin. Nous avons étudié l'effet d'un
analogue de l'angiotensine Ill (Aill), l'isoleucine-7 All! (lie7-
AllI), sur les réponses pressive et steroidogene a l'angiotensine
II (All) et l'A!Il. L'AIlI ou l'AIll (25 ng/kg/min) ont été perfusées
seules ou en méme temps qu'une perfusion d'-11e7-AIlI (100 ngl
kg/mm) a des lapins males, Nouvelle Zélande, éveillés. L'All
et l'All! déterminent des augmentations comparables de l'al-
dostérone plasmatique, mais All a un effet presseur sig-
nificativement supérieur. La perfusion d'lle7-AHl a pour
effet une inhibition significative de Ia steroidogenèse dépendante
de I'AII mais non de celle dépendante de Alit. Malgré l'inhibition
de Ia production d'aldostérone, l'11e7-Alll ne bloque pas l'effet
presseurou l'effet suppresseurde rénine del'All. L'inhibition de
l'effet steroidogéne de l'AH, mais non de celui de l'AIII, par l'IleT-
Alit peut être considérée coinme Ia preuve que Ia stimulation
surrénalienne par l'AII est directe et n'a pas pour médiateur sa
conversion in vivo en heptapeptide. La capacité de
l'heptapeptide analogue de bloquer Ia stimulation d'aldostérone
par l'octapeptide All suggère que les récepteurs surrénaux peu-
vent, cependant, avoir une aflinité plus grande pour l'heptapep-
tide que pour l'octapeptide.
It is generally thought that the effects of the renin-
angiotensin system are mediated by the interaction
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of angiotensin II (All) with specific receptors in vas-
cular smooth muscle, the kidney, and the adrenal
glomerulosa. Recent evidence suggests that the
heptapeptide des-aspartyl-1 All, termed angioten-
sin III (Alil), may also participate in the physiolog-
ic regulation of aldosterone secretion.
Blair-West et al [I] first demonstrated in short-
term infusion studies that All! was equipotent with
All in stimulating aldosterone production in the
sheep. Subsequently, the acute steroidogenic effect
of All! was demonstrated in the rat [2], dog [3], rab-
bit [4], and man [5]. Later, McCaa examined the
aldosterone response to prolonged infusion of A!!!
[6]. He found that following an initial marked in-
crease in plasma aldosterone concentration, pro-
longed infusion of Al!! over a period of 10 days re-
sulted in a sustained twofold increase in plasma al-
dosterone concentration in both sodium-replete and
sodium-deplete dogs. All produced a comparable
pattern of acute and long-term effects on aldoste-
rone secretion, without a significant pressor effect,
in sodium-deplete dogs [6]. In vitro studies have
demonstrated stimulation of aldosterone produc-
tion by All! in isolated adrenal zona glomerulosa
cells [7, 8] and specific saturable binding of A!!! to
subcellular membrane fractions of adrenal glomeru-
losa cells [9, 10]. The demonstration that A!!! is
generated from All in vitro [7] and from des-aspar-
tyl-l angiotensin I in vivo [11-13] and the finding of
significant concentrations of All! in arterial blood in
several species [14] raise the question whether Aill
plays a role in the regulation of aldosterone secre-
tion.
We previously reported that an analog of All,
sarcosyl-l-alanine-8-AII, was ineffective in inhib-
iting the steroidogenic response to All in the rabbit
at doses that completely blocked the pressor re-
sponse [15]. We suggested this to be a difference in
the specificity of angiotensin receptors in adrenal
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glomerulosa and vascular smooth muscle, the for-
mer having receptors with relatively greater affinity
for Alil, the latter for All. Bravo, Khosla, and
Bumpus [16] similarly found that an octapeptide an-
alog, Sar1,I1e8-AII, was relatively less effective in
blocking adrenal than vascular responses to All in
the dog. Goodfriend and Peach [7] and Freeman et
al [3] reported that the dose of octapeptide analog
required to inhibit Alil-induced steroidogenesis
was greater than that required to inhibit All-induced
steroidogenesis, suggesting a relatively greater af-
finity of adrenal receptors for the heptapeptide.
The hypothesis that adrenal receptors have hep-
tapeptide specificity and that vascular smooth
muscle receptors have octapeptide specificity de-
rives from studies with octapeptide analogs. The
hypothesis would predict that a specific heptapep-
tide antagonist would be more effective in blocking
adrenal than vascular smooth muscle responses to
angiotensin peptides. The present study was carried
out to examine the effects of a heptapeptide analog,
des-asp-l ile-8 A!! (Ile7-AI!I), on adrenal, renal,
and vascular responses to All and Aill. to further
characterize the specificity of angiotensin 'recep-
tors" in these tissues.
Methods
Studies were performed in male New Zealand
white rabbits weighing 2.9 to 5.9 kg and maintained
on a regular rabbit chow. Under local anesthesia,
the central ear artery was cannulated for blood sam-
pling and for measuring arterial pressure (Statham
pressure transducer). A continuous saline (0.9% so-
dium chloride) infusion was delivered through the
arterial catheter at a rate of 90d/min throughout the
experiment to maintain catheter patency. The mar-
ginal vein of the ear was cannulated for the infusion
at 20 p1/mm of 0.9% sodium chloride solution con-
taining 40 g/ml of dexamethasone to insure sup-
pression of ACTH release and for infusion of pep-
tides. Experimental protocols began with a control
period of 3 hours, during which the infusion con-
tained only dexamethasone in saline; the subse-
quent experimental periods were either 90 or 180
mm during which Ile7-AIII, All, or AIlI, alone or in
various combinations and doses, were added to the
ongoing dexamethasone infusion. The effects of
bleeding alone on mean arterial pressure (MAP),
plasma renin activity (PRA). and plasma aldoste-
rone concentration (PAIdO) were determined in a
group of 15 rabbits surgically prepared and bled in
the same manner as the experimental animals.
These sham-infused animals received a continuous
infusion of dexamethasone in saline but no peptide.
Eight sham-infused rabbits received a continuous
infusion of Plasmanate® at 90 /.Ll/min in place of the
saline used in all other studies. Blood samples (8 ml
each) were collected at the end of each period of
infusion. Blood samples for measurement of PRA
were collected into iced syringes containing 2,3-di-
mercaptopropanol and EDTA. Blood for measure-
ment of aldosterone was collected in heparinized
syringes. PRA was measured by the generation of
A! during 3 to 4 hours' incubation at 370 C and
native pH; the Al generated was measured by ra-
dioimmunoassay following extraction on Fuller's
earth [17]. Aldosterone was measured by radioim-
munoassay after solvent extraction and paper chro-
matography, based on the method of Mayes et al
[18]. Mean arterial pressure was estimated as the
diastolic pressure plus one third of the pulse pres-
sure. We dissolved 11e7-AIII, Alli, and All (pur-
chased from Schwartz-Mann) in phosphate-buf-
fered saline and stored them frozen at —20° C.
Comparisons within single protocols are by Stu-
dent's paired t test. Comparisons between two pro-
tocols are by Student's unpaired t test. Com-
parisons among more than two protocols are by
analysis of variance [19]. Indicated ranges are I
SEM. For PRA, all calculations and statistical com-
parisons have been performed on logarithms of the
measured values.
Results
Effect of blood sampling on PRA and P410 in
sham-infused rabbits. In 15 sham-infused rabbits
from which 8-mi samples of blood were taken at 90-
mm intervals, PRA increased stepwise from 1.53 ng
Al/mi/hr at the end of the control period to 7.33 ng
Al/mi/hr at the end of the third 90-mm study period.
PAldo also increased in successive samples from 3.2
0.5 ng/dl at the end of the control period to 11.9
1.8 ng/dl 270 mm later (see Fig. 3). The increases in
mean values above the control sample were signifi-
cant (P < 0.05) for all three subsequent PRA mea-
surements and for the second and third PAIdO mea-
surements. We could not confirm the finding of We-
ber, Thornell, and Stokes [20] that replacement by
colloid solution of blood removed in sampling pre-
vented an increase in PRA. No difference was seen
in PRA or PAIdO responses of sham-infused rabbits
receiving Plasmanate in place of saline, and the re-
suits in sham-infused rabbits receiving saline and
those receiving Plasmanate have therefore been
combined. The change in MAP from the control
(71.0 3.0 mm Hg) to the final period (64.3 2.3
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Fig. 1. Effect of isoleucine-7 angiofensin III (11e7-AIII) on PRA
andplasma aldosterone concentration (PA,d). Following an ini-
tial 3-hour control period, 11e7-A!!1 was infused at 100 ng/kg/min
(N = 26) or 1000 ng/kg/min (N = 21). Fifteen rabbits received
peptide-free infusion during a comparable 90-mm interval ("no
peptide"). Asterisks denote statistical significance of difference
from "no peptide, with < 0.01 and *** < 0.001.
mm Hg) was statistically significant (P < 0.05) but
small.
Agonist effects of lie 7-Alll (Fig. I). In 26 rab-
bits, Ile7-AIII was given at 100 ng/kg/min during
the first 90-mm period. PRA following infusion of
Ile7-AIII was lower than that seen in the sham-in-
fused animal (P < 0.01). PAIdO increased from 2.6
0.4 ng/dl to 5.9 0.6 ng/dl following infusion of lIe7-
AlIT; the increase was significant (P < 0.01) al-
though the increment did not differ significantly
from that observed in the sham-infused rabbits. In
21 rabbits, Ile7-AIII was administered at an infusion
rate of 1000 ng/kg/min during the first 90-mm peri-
od. PRA was again suppressed compared to the
sham-infused animals, but to no greater extent than
it was in the rabbits given 100 ng!kg!min. PALdO was
markedly increased by infusion of 11e7-AIII at 1000
ng/kg/min (Table I). The increase was significantly
greater than that seen in either the sham-infused an-
imals or those infused with 11e7-AIII at 100 ng/kg/
mm (P < 0.01). MAP did not change in the rabbits
infused with Ile7-AIII at either dose.
In 7 rabbits, 11e7-AIII was administered at 1000
ng/kg/min for an additional 180 mm to examine
whether the agonist effect on the adrenal was sus-
tained. At the end of the initial 90 mm of 11e7-AIII
infusion, PAIdO had increased from a control value of
5.4 1.4 ng/dl to 24.1 3.5 ng!dl (P <0.01). Fol-
lowing the subsequent 180 mm of continued in-
fusion of 11e7-A1II at the same rate, PAId0 averaged
17.3 3.5 ng/dl, a value not significantly different
from that at 90 mm (P> 0.2).
In 8 rabbits, the infusion of Ile7-AIII at 1000 ng/
kg/mm during the first 90-mm period was followed
by a 90-mm recontrol period during which no pep-
tide was given, to examine the duration of the agon-
ist effect of 11e7-AIII (Fig. 2). Mean PRA increased
from 1.54 ng AT/mi/hr to 5.86 ng Al/mi/hr and did
not differ from that in sham-infused animals 90 mm
after discontinuation of 11e7-AIII infusion. Mean
PAIdO decreased by 90 mm following cessation of
11e7-AIll administration, from 21.7 1.7 ng/dl to
17.6 3.2 ng/dl at the end of the recontrol period,
Table 1. Aldosterone responses to the infusion of A!!, A!II, and 11e7-AIP
PAIdO, ng/d!
No. of studies Control Agonist
11e7-A1II
100 ng/kg/min 180 mm
Agonist + !1e7-A!!I
100 ng/kg/min
All (25 nglkglmin) 18
10
6
3.2 0.5
2.5 0.5
3.0±0.6
54 l.4
21.2 2.7
—
19.4 3.6
5.0 1.2 12.0 1.5
All (25 ng/kg/min) 14
12
14
3.1 0.5
3.5 0.7
3.6 0.7
10.1 15b
14.3 2.3
—
20.4 2.3
5.7 1.0 14.9 2.5
11e7-AIH(l000ng/kg/min) 21
22
10
3.8 0.8
2.1 0.4
2.6 0.4
2.6 06b
18.9 1.5
—
14.2 1.1
6.8 1.0 10.0 1.1
a Values are the mean SEM.
h Value for PAIdO after 180 mm of peptide-free infusion.
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Fig. 2. Plasma aldosterone concentration (P4ldo foilos'ing cessa-
tion of 11e7-AIll infusion. Following a 3-hour control period, lIe7-
AIll (1000 nglkg/min) was infused for 90 mm. PAId0 was measured
following analog infusion and again 90 mm after cessation of ana-
log infusion. The response following cessation of AIlI infusion,
reported previously [4], is shown for comparison.
but was still significantly higher than the corre-
sponding value in the sham-infused rabbits (10.5
1.3 ngldl, P < 0.05). The slow decline in PAIdO fol-
lowing discontinuation of infusion of 11e7-AI1I dif-
fered from the rapid return of PAId0 to basal levels
following discontinuing an equally steroidogenic in-
fusion of Alil reported in our previous studies [4]
and presented for comparison with the present data
in Fig. 2.
We attempted to examine the dose-response
characteristics of 11e7-AIII's agonistic effect on al-
dosterone secretion by infusing it in sequential 90-
mm periods at rates of 100, 300, and 1000 nglkg/min
(N = 9, Fig. 3). In contrast to the increase in PAId0
observed when 11e7-AIII at 1000 ng/kglmin was giv-
en as the initial infusion (PAIdO = 15.2 1.3 ng!dl;
N = 21), an increase of PA1dO that averaged only 6.1
1.7 ngldl occurred when 11e7-AIII was given at the
same dose following prior sequential infusions at
100 and 300 ng!kg!min. In 13 additional rabbits we
examined the effect of prior infusion at 100 nglkgl
mm for 90 mm (N = 5) or 180 mm (N = 8) on the
steroidogenic response to the infusion at 1000 ng/kg!
mm. The results were comparable to those seen in
the group of 9 rabbits given sequential infusions at
100 and 300 ng!kg/min and have therefore been
combined for analysis (N = 22, Fig. 4, Table 1). The
increase in PAid0 observed in response to 11e7-AIII
given at 1000 ng/kglmin following infusion of Ile7-
Fig. 3. Aldosterone dose-response to infusion of lie 7-Alll. Fol-
lowing a 3-hour control period, 9 animals received successive 90-
mm infusions of 1le7-Al1l at 100, 300, and 1000 ng/kglmin. The
values for PAIdO in sham-infused rabbits are shown for com-
parison.
First
infusion
11e7-AlIl
1,000 ny/kg/mm
11e7-AIII
100 ng/kg/min
Saline
Second 11e7-AIII 1le7-AllI
infusion 1,000 ny/kg/mm 1.000 ny/kg/mm
Fig. 4. lnhibition of the steroidogenic response to 'high-dose"
11e7-Alll (/000 ng/kg/min) by "low-dose" lie7-Al!I (/00 ng/kg/
mm). The aldosterone response to 11e7-AIII at 1000 ng/kg/mmn
following a prior 90- or 180-mm infusion of 11e7-AIII at 100 ng/kg/
mm (center shaded bar) was significantly less than that observed
when 11e7-AIII (1000 ng/kg/min) was given immediately following
the 3-hour control period (open bar on left) or after a l80-min
period of peptide-free infusion (open bar on the right).
Aill at either lower dose averaged 7.8 1.1 ng/dl, a
value significantly lower than that observed when
Ile7-AIII at 1000 ng!kg/min was given as the initial
infusion. We attempted to ascertain whether the
smaller increase in PAIdO represented a true inhibi-
tion of the steroidogenic response to the higher dose
of 11e7-AlII by prior administration of a lower dose
rather than a "nonspecific" decrease in adrenal re-
sponsiveness related to the more prolonged period
3.0 6.0
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of the study prior to administration of 11e7-AIII at
1000 ng/kg/min. In 10 animals, a 180-mm period of
peptide-free infusion preceded the administration of
11e1-AIII at 1000 ng/kg/min; the observed increase
in PAIdO averaged 11.5 1. 1 ngldl, a value not signif-
icantly different from that in animals receiving lIe7-
AlIT at 1000 ng!kglmin in the initial period (0.05 <P
<0.10). Compared with the pooled values for rab-
bits receiving IleT-AIII at 1000 nglkglmin in the ini-
tial period (open bar on the left of Fig. 4) and for
those receiving the same dose following 180 mm of
peptide-free infusion (open bar on the right of Fig.
4), there was a significant inhibition of the steroido-
genic response (P < 0.01, center shaded bar of Fig.
4) by the prior administration of Ile7-AIIl at 100
nglkg/min. When the experimental group (Fig. 4,
center bar) was compared with the latter group of
controls only, the difference between them was of
marginal significance (P = 0.05).
Although a prior infusion of Ile7-AIII at 100 nglkgl
mm caused partial inhibition of the steroidogenic re-
sponse to the higher dose (1000 ng/kglmin), it did
not fully block the agonistic effect of the higher dose
on the adrenal. Studies designed to examine the an-
tagonistic effect of the heptapeptide analog on All-
and Alil-induced steroidogenesis were therefore
limited to the infusion of the lower dose of the ana-
log (100 ng/kg/min).
Antagonist action of lie 7-AllI on All-induced ste-
roidogenesis (Fig. 5). The infusion of All (25 ng/kg/
mm) during the initial 90 mm in 18 rabbits resulted
in an increase in PAIdO from 3.2 0.5 ng!dl to 21.2
2.7 ng/dl, a decrease in PRA from 1.99 to 0.69 ng Al/
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First All 11e7-A1lI Salineinfusion 25 ng/kg/min 100 ng/kg/min
Second 1le7-AIII + All All
infusion 100 nglkg/min 25 ng/kg/min 25 ny/kg/mm
Fig. 5. Inhibition of All-induced steroidogenesis by 11e7-A Ill. Re-
sponses to All (25 nglkglmin) given during the initial 90-mm in-
fusion period (left) and following 180 mm of peptide-free infusion(right) do not differ significantly. The response when All was
superimposed on a prior infusion of 11e7-AHI (100 nglkglmin) was
significantly decreased (P < 0.01, center, shaded).
8
mllhr, and an increase in MAP from 69.5 1.9 mm
Hg to 80.2 2.3 mm Hg. When 11e7-AIIl was given
at a rate of 100 nglkg!min for 180 mm prior to and
during All infusion (N = 10), PAIdO increased by on-
ly 7.0 1.1 ng/dl, a value significantly less than that
in rabbits receiving All alone (P < 0.01). To ascer-
tain whether the smaller increase in PAldo represent-
ed true inhibition of All-induced steroidogenesis
rather than a decreased adrenal responsiveness to
All related to the more prolonged period of infusion
prior to All administration, we gave an additional
group of rabbits (N = 6) All at the same dose (25 ng/
kglmin) following 180 mm of peptide-free infusion.
PAIdO increased by an average of 14.0 3.0 ng/dl in
these animals, a value not significantly different
from that in the larger group of 18 rabbits receiving
All during the initial 90 mm. The aldosterone re-
sponse of animals infused with 11e7-AIII at 100 ng/
kg/mm prior to and during All infusion was signifi-
cantly inhibited (P < 0.01) whether compared with
the combined group of rabbits receiving only All or
either subgroup (bars on left and right of Fig. 5).
Suppression of PRA (from 1.04 to 0.56 ng/ml/hr)
in rabbits in which All infusion was superimposed
on 11e7-AIII was not significantly different from that
observed when All was given alone. The increase
of MAP (from 55.6 2.6 to 72.8 4.0 mm Hg)
when All was given during administration of lIe7-
AIlI was no less than that observed when All was
given alone (Fig. 6).
Effect of lie 7-AIII on Alli-induced steroidogene-
sis (Fig. 7). The infusion of Alli at 25 ng/kg/min for
90 mm resulted in an increase in mean PAIdO of 11.2
2.5 ng/dl (N = 14). AIlI infusion following 180
mm of peptide-free infusion resulted in a com-
parable increase in PAId,, (10.3 2.7 ng/dl, N = 14).
In contrast to the findings with All, the steroidogen-
Ic response to Aill was not inhibited by prior ad-
ministration of Ile7-AIII at 100 ng/kglmin for 90 or
180 mm. When tle7-AIII was infused for 90 or 180
mm before and during Alil administration at 25 ng!
kg/mm, PAIdO increased by 9.2 2.4 ng/dl (N = 12),
a response not significantly different from that in
rabbits receiving Alil alone.
Infusion of Alli at 25 ng/kg/min for 90 mm result-
ed in a small, statistically insignificant, fall in PRA.
Compared with the increase observed in sham-in-
fused animals (Fig. 1), however, PRA was signifi-
cantly lower in rabbits given Alil (P < 0.05). PRA
was similarly suppressed by Ile7-AIII infusion, as
compared with sham-infused animals, and remained
suppressed during the combined infusion. MAP in-
creased 2.5 1.4 mm Hg during infusion of AIlI
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Fig. 6. Failure of 11e7-A Ill to inhibit the pressor response to All.
All at 25 nglkg/min exerted a significant pressor effect whereas
Alli, at the same dose, did not cause significant increase in mean
arterial pressure (MAP). The pressor response to All was not
diminished by administration of 11e7-AIll.
First lIe7 -Alit -
infusion 100 ng/kg/min Saline
Second 11e7-Attl + Alit Alit
infusion 100 nglkglmin 25 nglkg/min 25 ng/kglmin
Fig. 7. Failure of lie 7-Alll to inhibit AlIl-induced steroid-
ogenesis. Responses to AIll (25 ng/kg/min) given during the ini-
tial 90-mm infusion period (left) and following 180-mm of pep-
tide-free infusion (right) do not differ. The response was not in-
hibited when All! was superimposed on a prior infusion of LIe7-
Alit (center, shaded).
alone, and by 1.8 1.0 mm Hg when the Alli was
added to a continuing infusion of Ile7-AIII. These
increases do not differ significantly. They do differ
significantly from the small decreases of MAP seen
in the sham-infused animals, and they demonstrate
the modest pressor effect of Alli.
Discussion
Structural analogs of Al!, which act as com-
petitive antagonists at specific receptors, provide an
experimental tool for examining the role of angio-
tensin in the mediation of a variety of physiologic
responses. The findings of such studies are com-
plicated, however, by the fact that many of these
analogs, under some circumstances, also stimulate
angiotensin receptors, that is, they behave as partial
agonists. The present data demonstrate that lIe7-
All!, an anlog of Alil, also acts as a partial agonist.
When infused at a rate of 1000 ng!kglmin, 11e7-AIII
results in stimulation of aldosterone secretion and
suppression of renin release without substantial
blood pressure change in the sodium-replete rabbit.
This pattern of end-organ responses is similar to
that observed in this and in our previous study [4]
with infusion of A!!! at 25 nglkg/min in the sodium-
replete rabbit. That 11e7-AIlI should possess agonis-
tic properties is not surprising because carboxyter-
minal isoleucine analogs of the octapeptide All also
exhibit significant agonistic activity [21].
The fact that the lower dose of 11e7-AIII used in
the present studies resulted in only a small increase
in PAIdO allowed us to examine the antagonistic ef-
fects of the analog; the greater agonistic effect of
11e7-AIIl at higher doses prevented examination of
the full range of antagonistic activity. The infusion
of 100 ng!kglmin of lle7-AIII significantly inhibited
the steroidogenic response to superimposed in-
fusion of All but not of A!!!. Although a full antago-
nistic dose-response was not determined, this find-
ing suggests that in the dose range of angiotensin
peptides used (25 nglkglmin), the affinity of adrenal
receptors for A!! is less than that for All!, because
Ile7-AIlI was more effective in blocking the ste-
roidogenic effect of the octapeptide, All, than
of the heptapeptide, All!. This finding complements
the findings of others [3, 22] who reported that
the dose of an octapeptide analog required to
block Aill-induced steroidogenesis was greater
than that required to block the steroidogenic re-
sponse to All, again suggesting greater affinity of
adrenal receptors for the heptapeptide.
The finding that !1e7-AIII inhibited All-induced
but not Alli-induced steroidogenesis allows a fur-
ther conclusion regarding the role of these two
forms of angiotensin in the regulation of aldosterone
production. Based on the finding that All! is as po-
tent as All in stimulating aldosterone production,
we [4] and others [3, 7] have speculated that All
might be converted to the heptapeptide by tissue
angiotensinases, known to be present in the adrenal
gland, and mediate steroidogenesis through recep-
tors with heptapeptide specificity. The present dem-
onstration that All-induced steroidogenesis is in-
hibited by 11e7-AIII, whereas Alil-induced steroido-
genesis is unaffected argues strongly against the
hypothesis that All acts via prior conversion to
A!!!. Douglas et al [23] found that after All stimula-
tion of isolated canine adrenal glomerulosa cells,
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the peptide could be eluted, largely unchanged, and
they concluded that conversion of A!! to AIlI was
not a necessary step in adrenal stimulation. Our
data, taken together with those of Douglas et al [23],
suggests that both All and Alil may act directly on
adrenal receptors to stimulate aldosterone produc-
tion. It is not known whether the octapeptide and
the heptapeptide react with the same or different re-
ceptors. Carey et al [24] found that steroidogenic
responses to All and Aill were additive and con-
cluded that adrenal receptors for these two peptides
were different. In vitro, Devynck et al [9] described
two classes of binding sites for tritiated angiotensin
peptides in particulate fragments of rat adrenal. A
small number of sites, of high affinity, demonstrated
specificity for AlIT. A second group of sites, of
lower affinity but greater capacity, manifested simi-
lar affinities for All and At!!. Our finding that All-
induced steroidogenesis is inhibited more readily by
an Alli analog than is Alit-induced steroidogenesis
would fit equally well with the proposal of Devynck
et al or a model in which All and All! are bound
with differing affinities to the same receptor.
The finding that the steroidogenic response to
I1e7-AIII given at 1000 nglkg!min was reduced by
prior infusion of the same analog at a lower rate (100
nglkglmin) cannot be readily accounted for if lIe7-
A!!! is viewed as acting solely as a partial agonist,
that is, as an analog with lower intrinsic activity
than the naturally occurring agonist and capable of
competing with the natural agonist for occupancy of
receptors. The report that the prior infusion of Sar1,
A1a8-AII at a low rate (0.01 to 0.10 g!kg/min) for 30
mm significantly inhibited the immediate pressor re-
sponse to the infusion of the same analog at a higher
rate (10 gIkg!min) in hypertensive subjects [25]
suggests that this effect of angiotensin analogs may
not be limited to the heptapeptide analog 11e7-AIII,
nor to responses of the adrenal glomerulosa. Agon-
ists or analogs with partial agonistic activity have
been shown to induce functional loss of receptors
for insulin [26] catecholamines [27], and other hor-
mones. Inhibition of the steroidogenic response to
11e7-AIII by prior low-dose infusion might represent
inactivation of receptors by this partial agonist. Al-
ternatively, 11e7-AIII, at low dose might induce
negative cooperativity" [28] in unoccupied adre-
nal receptors and thereby reduce responsiveness to
11e7-AIII during subsequent high-dose infusion.
The results of the present studies, using an analog
of the heptapeptide All!, contrast in several re-
spects with our earlier findings utilizing the octa-
peptide analog Sar',A1a8-A!I [15] and provide addi-
tional evidence of differences among adrenal, vas-
cular, and renal receptors for angiotensin. We
reported previously that the octapeptide analog,
Sar',Ala8-AII, was a relatively ineffective inhibitor
of All-induced aldosterone secretion in the rabbit
[15]. Williams et al [29] and Bravo, Khosla, and
Bumpus [30] also found that the octapeptide ana-
logs Phenyl4,Tyr8-AII and Sar1,Ile8-AII, at infusion
rates which inhibited the effects of All on vascular
smooth muscle, were relatively weak antagonists of
All-induced steroidogenesis. The present finding,
that the heptapeptide analog 11e7-AIII is capable of
significant inhibition of All-induced steroidogenesis
at a dose that did not decrease the pressor response,
may be taken as further evidence that the adrenal
receptor has a relatively greater affinity for the hep-
tapeptide than for the octapeptide, that is, that adre-
nal receptors have heptapeptide specificity.
The effect of the heptapeptide analog on renin
secretion appears to differ from that observed pre-
viously with the octapeptide analog Sar',Ala8-AII.
We have previously reported that Sar',Ala8-AII
evoked a significant increase in PRA in sodium-
replete rabbits and attributed this response to analog
inhibition of short-loop feedback regulation of renin
release by All [15]. The failure to observe increased
renin release during administration of 11e7-AIII and
the finding that when superimposed on a prior in-
fusion of 11e7-AIII, All was still able to cause sup-
pression of renin release indicate that this analog
does not compete effectively with All for receptors
regulating renin release.
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